Compare HP Inc (HPQ) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Incyte Corporation — how do they compare? HP Inc trades at $24.82 (market cap $22.15B), while Incyte Corporation trades at $117 (market cap $23.11B). The key difference: HP Inc and Incyte Corporation are close in size by market cap, and HP Inc pays a 4.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| HPQ | INCY | |
|---|---|---|
Market Cap | $22.15B | $23.11B |
Sector | Technology | Health |
52-Week High | $29.35 | $118.52 |
52-Week Low | $18.20 | $67.38 |
Enterprise Value | $29.31B | $19.13B |
Dividend Yield | 4.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $24.81, down 0.12% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows attractive valuation with a P/E of 8.97 and P/S of 0.4, supported by consistent earnings beats in recent quarters. Recent news highlights AI-driven upgrade cycles and strategic partnerships, including with OpenAI, positioning HP for growth in the AI PC market. Cash flow trends have improved, with net cash flow turning positive in 2025.
The outlook for HPQ is cautiously optimistic, driven by potential AI PC adoption and solid fundamentals, but risks include competitive pressures and cyclical demand. Analyst consensus is mixed with a hold rating, and the current price is above the consensus target of $22.00, suggesting limited near-term upside. Investors should weigh the dividend yield and valuation against market volatility and execution risks.
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
